SIL-4 Cognitive Medical OS · Patent-pending · Operational
The bill for the status quo
Every year the system pays, in full, for the exact problems this platform removes. The money is already being spent. It is simply being spent on the damage.
Sources: Newman-Toker et al., BMJ Quality & Safety 2023; Society to Improve Diagnosis in Medicine; AMA / Shanafelt et al., Annals of Internal Medicine; industry trial-recruitment and delay-cost studies; Cutler & Summers, JAMA 2020; Nori et al. 2025 (SDBench, sequential protocol).
What no one else can claim
The certified worst-case probability of an undetected hallucination reaching a conclusion: one in 309,600 assertions, derived by fault-tree analysis per IEC 61025, not asserted by marketing. Under nominal conditions: one in 5.9 million.1
Every conclusion ships with a court-grade evidentiary record on DeepSensi’s exclusive, proprietary, patent-pending audit ledger: each step attributed to AI, physician, or rule, cryptographically sealed, tamper-proof even against the operator.
A specialist counterpart for every discipline of medicine deliberates adversarially under independent judges, and physicians join as scored, compensated nodes. The reach of a teaching hospital, in 12 seconds to a few minutes.
The diagnosis that recruits. The instant a phenotype is recognized, the patient is matched to a clinical trial or a compassionate-access route. Enrollment starts at diagnosis, not months later.
Who it is for
Physicians
A full specialist consilium in seconds, and a court-grade record behind every decision you make. DeepSensi is your exosuit, not your replacement. And it opens a new economy: royalties when your clinical insight helps a patient anywhere on Earth.
What changes for youPatients
A university-grade second opinion for your case, in your language, in seconds, with every conclusion backed by evidence and never a guess. And medicine that remembers you: an alert can reach you years after a visit, when a new finding finally connects the dots.
What it means for youClinics & Hospitals
Department-grade intelligence with zero new headcount. EHR plug-and-play, insurable AI risk, EU AI Act ready by architecture, and documentation that writes and codes itself.
Deploy in your departmentNational Health & NGOs
GERN turns ordinary clinical encounters into DeepSensi’s exclusive epidemic radar: physician-level early warning that crosses borders, built from the notes doctors already write. Open, royalty-free, auditable, private by architecture.
The exclusive epidemic radarPharma
Verified-evidence discovery, population-scale simulation, and real-time trial matching at the exact moment of diagnosis, on six continents.
Attack the denominatorInsurers & Regulators
The first clinical AI with a quantified, SIL-4-grade error bound, liability partitioned per decision, and 100 percent audit coverage of every assertion. Governed by the Gomola Framework, an open, royalty-free certification standard.
The DeepSensi StandardThe proof, the standard, the audit
On the publicly available NEJM Clinicopathological Conference cases, the diagnoses that stump specialists, DeepSensi does not just score well. It refuses to miss the ones that matter.
DeepSensi: 86.0% top-1, 93.7% top-3 on 301 NEJM CPC cases (2014 to 2023), development-cohort. Blinded inputs: every case was stripped of its title, names, and dates before entering the system, and training-set leakage is controlled by design; protocol and case-level adjudications are published in Supplement S1. MAI-DxO, o3, GPT-4o, physicians: SDBench, 304 cases (Nori et al. 2025). 1 Certified worst-case bound 3.23 × 10⁻⁶ per assertion, meeting the IEC 61508 SIL-4 demand-mode target. 2 development-cohort; a confirmatory study is designated. We publish the proof, the standard, and the audit. We do not publish the blueprint.
Proof in motion
Multi-site, silent-mode, non-interventional. Pre-registered before the first patient, adjudicated by an independent blinded committee, reported to the STARD-AI standard whatever the results. Hospitals join as named study sites.
The investment inversion
In the same NEJM CPC case family, this is what reaching one diagnosis costs today, in ordered diagnostic tests (sequential protocol, Nori et al. 2025):
Different protocol, honestly stated: SDBench orders tests sequentially; DeepSensi reasons from the presented record - and when evidence is genuinely missing, LIMBO names the single test that settles the case, not a battery. That is the inversion: no test cascade to pay for, and a consilium engineered to run on commodity infrastructure at a per-case cost hundreds of times below the bills above - under one percent of them, stated deliberately as a bound, not as “free.” Certainty at a fraction of what the market already pays for guesswork; deployment pricing is quoted per pilot.